Trials / Recruiting
RecruitingNCT06423885
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open-label, phase II clinical study to explore the safety and efficacy of BL-M07D1+PD-1 monoclonal antibody in patients with unresectable locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-M07D1 | Administration by intravenous infusion for a cycle of 3 weeks. |
| DRUG | PD-1 monoclonal antibody | Administration by intravenous infusion for a cycle of 3 weeks. |
Timeline
- Start date
- 2024-12-24
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2024-05-21
- Last updated
- 2025-08-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06423885. Inclusion in this directory is not an endorsement.